RxDoctor Payments Data

Cassia Schmid

Psychiatric/Mental Health · Pensacola, FLNPI 1205539202

Payments from drug & device makers

$2,243in general payments, 2019–2025

Across 92 payments — averaging $24.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$440
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$377
  • Alkermes, Inc.$285
  • E.r. Squibb & Sons, L.L.C.$224
  • Otsuka America Pharmaceutical, Inc.$171
  • Johnson & Johnson$128
  • plus $618 from 10 others

What the payments were for

  • Food & beverage$2,243100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,243 in reported general payments places this provider in the 75th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$15,745
Medicare patients
65
Services billed
206

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl53$74,807
TrintellixVortioxetine Hydrobromide23$21,258
AuvelityDextromethorphan Hbr/Bupropion12$13,302
Aripiprazole105$4,891
Lurasidone Hcl27$3,022
Desvenlafaxine Succinate ErDesvenlafaxine Succinate26$1,849
Venlafaxine Hcl ErVenlafaxine Hcl54$1,576
Clonazepam135$1,314
Trazodone Hcl143$1,276
Prazosin Hcl60$1,256
Hydroxyzine Pamoate53$1,221
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine21$1,212
Duloxetine Hcl55$1,197
Buspirone Hcl70$1,168
Quetiapine Fumarate52$1,048

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$440$74,80753 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$22$21,25823 claims
Axsome Therapeutics, Inc.Auvelity$58$13,30212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Pensacola

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →